Dudley & Shanley Inc. Has $22.79 Million Stake in Danaher Corporation $DHR

Dudley & Shanley Inc. boosted its holdings in Danaher Corporation (NYSE:DHR) by 4.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 114,941 shares of the conglomerate’s stock after buying an additional 5,389 shares during the period. Danaher makes up about 3.7% of Dudley & Shanley Inc.’s investment portfolio, making the stock its 13th biggest position. Dudley & Shanley Inc.’s holdings in Danaher were worth $22,788,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock valued at $12,004,424,000 after acquiring an additional 788,499 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Geode Capital Management LLC lifted its stake in Danaher by 0.6% in the second quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock valued at $2,697,800,000 after buying an additional 81,670 shares during the period. Norges Bank bought a new position in Danaher during the second quarter worth about $1,979,503,000. Finally, Generation Investment Management LLP grew its position in shares of Danaher by 56.2% during the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after buying an additional 1,787,522 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on DHR. Redburn Partners set a $220.00 price target on shares of Danaher in a research report on Wednesday, October 8th. TD Cowen lifted their price target on shares of Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Jefferies Financial Group raised their price objective on Danaher from $245.00 to $255.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Royal Bank Of Canada set a $241.00 target price on Danaher in a research note on Tuesday, September 2nd. Twenty investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus price target of $248.25.

Danaher Trading Down 0.8%

DHR opened at $222.91 on Thursday. The stock has a market capitalization of $157.45 billion, a P/E ratio of 45.96, a P/E/G ratio of 4.36 and a beta of 0.89. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The firm’s fifty day simple moving average is $219.53 and its 200 day simple moving average is $206.53.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $1.71 EPS. As a group, research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s payout ratio is presently 26.39%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This trade represents a 59.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,248 shares of company stock valued at $6,609,663 in the last quarter. 11.10% of the stock is currently owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.